Back to Search
ANDREW OLIFF, M.D.
M.D.
Anatomic Pathology Physician
NPI: 1255485611IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anatomic Pathology PhysicianPrimary
Pathology — Anatomic Pathology
Code: 207ZP0101X
215916(NY)
CMS Specialties
PrimaryPATHOLOGY
Education
STATE UNIVERSITY OF NEW YORK AT BUFFALO SCHOOL OF MEDICINE
Class of 1997
Research & Publications (13)
Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than doxorubicin with less toxicity.
PMID 15897239·Mol Cancer Ther·2005
7-preclinical
Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity.
PMID 12361397·J Med Chem·2002
7-preclinical
A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo.
PMID 12479263·Mol Cancer Ther·2002
7-preclinical
The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
PMID 11708923·J Med Chem·2001
7-preclinical
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
PMID 11181501·Drug Metab Dispos·2001
7-preclinical
Signaling pathways in apoptosis as potential targets for cancer therapy.
PMID 11489640·Trends Cell Biol·2001
6-review
Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer.
PMID 12497061·Prostate Cancer Prostatic Dis·2001
8-other
Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
PMID 11751396·Cancer Res·2001
4-observational
Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor.
PMID 10825141·Cancer Res·2000
7-preclinical
A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo.
PMID 11062536·Nat Med·2000
7-preclinical
Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.
PMID 10931682·Radiat Res·2000
7-preclinical
Farnesyltransferase inhibitors: antineoplastic properties, mechanisms of action, and clinical prospects.
PMID 11170866·Semin Cancer Biol·2000
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 506 6TH ST
BROOKLYN, NY 11215 - Phone
- (718) 780-3659
Quick Facts
- NPI
- 1255485611
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 29
- Publications
- 13
Are you this provider?
Claim Your Profile